Daewoong Pharma to build third botulinum toxin plant for $746 mn

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cost of over 100 billion won ($746 million).

The company on Tuesday said the facility will boost production by 13 million units to expand Nabota's business.

Daewoong Pharmaceutical's two factories produce a combined five million bottles of Nabota per year. When the third is completed in the town of Hyangnam in Hwaseong, Gyeonggi Province, production will jump 260% to 18 million per year.

The goal is to start construction in the first half of this year for completion next year.

The new plant will also boost output capacity by optimizing process design to churn out not only conventional formulations but also those of the next generation such as liquid, continuous and microneedles.

Write to Ji-Hyun Lee at bluesky@hankyung.com